Gaoling is selling BeiGene shares to cash out at least $3.7 billion, and plans to subscribe for new shares of Hengrui Medicine.

Taking advantage of the rebound in stock prices, Hillhouse Capital has reduced its holdings of BeiGene's US stocks multiple times this year. On the evening of May 14th, BeiGene announced that Hillhouse Capital's platform once again reduced its stake in the company. According to BeiGene, this time Hillhouse Capital reduced its holdings in the company's US stock. Based on the lowest price of $230.23 per share on May 9th, the funds cashed out by Hillhouse Capital from its stake in BeiGene could reach $3.68 billion. It is noted that after this reduction in BeiGene's shareholding, Hillhouse Capital is turning to subscribe to the Hong Kong IPO of Hutchison MediPharma.